Company intelligence / Profile preview
Taiga Biotechnologies, Inc.
Aurora, Colorado, United States
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Taiga has multiple clinical programs, with TBX-2400 in Phase 1/2 for Acute Myeloid Leukemia. The company has treated its first cancer patient in the TBX-3400-003 clinical trial in Israel for colorectal cancer. The US study (TBX-3400-001) is enrolling patients with stage III or IV melanoma which has become refractory or resistant to immune checkpoint inhibitors[6][10].
- Therapeutic areas
- OncologyInfectious DiseasesImmunologyHematology
- Modalities
- Cell therapyHematopoietic stem cell therapyRecombinant protein
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Taiga Biotechnologies, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Taiga Biotechnologies, Inc..